Prof Lorenzen is a consultant at the Department of Hematology and Oncology and Head of the Early Clinical Trial Unit, Klinikum Rechts der Isar, Technische Universität  München, Munich, Germany.

Her clinical research interests include medical oncology, response evaluation in solid tumour therapy, multimodality treatment of gastrointestinal cancer and Phase I clinical trials. She has served as Principal Investigator or Sub-Investigator of multiple studies in the field (investigator-initiated trials and industry-sponsored registration studies).

Prof Lorenzen is chair of the Gastric Cancer Task Force of the Arbeitsgemeinschaft Internistische Onkologie (AIO; German Cancer Society), and a member of the Educational Steering Committee of the European Society for Medical Oncology (ESMO) and the Bavarian Ethics Commission. She is also designated Investigator of the German Consortium for Translational Research (DKTK), the Spokesperson and Coordinator of the German Gastric- and Esophageal Cancer Guidelines (S3-Leitlinien), First-author of the German Onkopedia Guidelines, Coauthor of the ESMO Gastroesophageal Cancer Guidelines (in preparation) and speaker for the BZKF Gastroesophageal Working Group.

Prof Lorenzen is a scientific advisor/reviewer for a number of journals including Annals of Oncology, Annals of Surgical Oncology, Oncology, European Journal of Nuclear Medicine and Expert Opinion on Emerging Drugs. I am Review Editor for Frontiers in Oncology and has been Editor-in-Chief of the Journal Oncology Research and Treatment since 2020.